Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DarbeLus: Luspatercept Plus Darbepoetin Alfa in Lower-risk MDS
NCT07096297Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Dec 2025
- Primary completion
- Aug 2030
- Modality
- Colony Stimulating Factors, Erythropoietins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of luspatercept, darbepoetin alfa in myelodysplastic syndrome (MDS), sponsored by Yale University. Started Dec 2025; status: recruiting.
02
Drugs
luspaterceptdarbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07096297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096297.